CDP323 is a small-molecule prodrug antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to α4-integrins. It was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and was a putative new drug for oral treatment of multiple sclerosis.
In October 2006, UCB and Biogen Idec announced a collaboration to jointly develop and commercialize CDP323 for the treatment of multiple sclerosis and other potential indications. In June 2009, development of CDP323 was discontinued due to discouraging results of a Phase II clinical trial.
Read more about CDP323: Mechanism of Action, Results in Animal Models, Clinical Development, 30 June 2009: End of Trial